<p>Dyne Therapeutics, Inc.（納斯達克代碼：DYN - 免費報告）- HC Wainwright 的投資分析師在 5 月 12 日星期二向投資者發佈的報告中上調了 Dyne Therapeutics 2026 年第二季度每股收益（EPS）預期。HC Wainwright 分析師 A. Ghosh 現在預計該公司本季度每股收益為（$0.68），高於之前的預期（$0.76）。HC Wainwright 對該股票給予 “買入” 評級，目標價為 $50.00。市場普遍預計 Dyne Therapeutics 當前全年的每股收益為（$2.97）。HC Wainwright 還發布了 Dyne Therapeutics 2026 年第三季度每股收益預期為（$0.68），第四季度每股收益預期為（$0.68），2026 財年每股收益預期為（$2.78），2027 財年每股收益預期為（$2.27），2028 財年每股收益預期為（$0.85），2029 財年每股收益預期為 $0.52，2030 財年每股收益預期為 $2.26。</p>
<p>獲取 <strong>Dyne Therapeutics</strong> 警報：</p>
<p>Dyne Therapeutics（納斯達克代碼：DYN - 獲取免費報告）上一次發佈季度財報是在 5 月 11 日星期一。該公司報告本季度每股收益為（$0.73），超出市場普遍預期的（$0.77）$0.04。在去年同期，該公司每股收益為（$1.05）。</p>
<p>其他一些研究公司也對 DYN 發佈了報告。摩根士丹利在 3 月 2 日的研究報告中將 Dyne Therapeutics 的目標價從 $50.00 下調至 $47.00，並對該股票給予 “增持” 評級。Chardan Capital 在 3 月 9 日的研究報告中重申了 “買入” 評級，並對 Dyne Therapeutics 的股票設定了 $38.00 的目標價。華爾街 Zen 在 5 月 2 日的研究報告中將 Dyne Therapeutics 的股票評級從 “賣出” 下調至 “強烈賣出”。Weiss Ratings 在 4 月 20 日的研究報告中重申了對 Dyne Therapeutics 的 “賣出（d-）” 評級。最後，傑富瑞金融集團在 3 月 9 日的研究報告中重申了對 Dyne Therapeutics 的 “買入” 評級。三位投資分析師對該股票給予了強烈買入評級，十一位給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Dyne Therapeutics 目前的共識評級為 “適度買入”，平均目標價為 $35.21。</p>
<p><strong>獲取我們關於 Dyne Therapeutics 的最新研究報告</strong></p>
<h2>Dyne Therapeutics 股票上漲 0.4%</h2>
<p>Dyne Therapeutics 股票在星期四開盤價為 $18.44。該公司的市值為 $30.5 億，市盈率為 -5.73，貝塔值為 1.08。該公司的 50 日簡單移動平均線為 $18.22，200 日簡單移動平均線為 $18.63。該公司的流動比率為 19.92，速動比率為 22.25，債務與股本比率為 0.17。Dyne Therapeutics 的一年低點為 $8.06，一年高點為 $25.00。</p>
<h2>機構投資者對 Dyne Therapeutics 的看法</h2>
<p>幾家對沖基金最近對該股票的持倉進行了調整。Dimensional Fund Advisors LP 在第一季度將其在 Dyne Therapeutics 的股份增加了 870.3%。Dimensional Fund Advisors LP 現在擁有 951,589 股該公司的股票，價值 $17,244,000，此前在此期間又購買了 853,515 股。瑞士國家銀行在第一季度將其在 Dyne Therapeutics 的股份增加了 2.5%。瑞士國家銀行現在擁有 228,100 股該公司的股票，價值 $4,135,000，此前在此期間又購買了 5,600 股。Assetmark Inc. 在第一季度購買了 Dyne Therapeutics 的新股份，價值約 $563,000。紐約梅隆銀行在第一季度將其在 Dyne Therapeutics 的股份增加了 13.6%。紐約梅隆銀行現在擁有 401,616 股該公司的股票，價值 $7,281,000，此前在此期間又購買了 48,119 股。最後，Fifth Third Bancorp 在第一季度購買了 Dyne Therapeutics 的新股份，價值約 $983,000。機構投資者持有該公司 96.68% 的股份。</p>
<h2>Dyne Therapeutics 的內部買賣</h2>
<p>在相關消息中，董事 Jason P. Rhodes 於 5 月 6 日星期三出售了 83,219 股該股票。股份以平均價格 $18.18 出售，總價值為 $1,512,921.42。出售完成後，該董事在公司中持有 7,962 股，價值約 $144,749.16。此交易代表其持股比例減少了 91.27%。該交易已在證券交易委員會的備案中披露，可以通過此超鏈接訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。內部人士在過去三個月內共出售了 1,552,911 股公司股票，價值 $29,694,469。目前公司內部人士持有 14.14% 的股票。</p>
<h2>更多 Dyne Therapeutics 新聞</h2>
<p>以下是本週影響 Dyne Therapeutics 的主要新聞：</p>
<ul>
<li>積極情緒：HC Wainwright 和 Lifesci Capital 都上調了 Dyne Therapeutics 的近期收益預期，包括 2026 年第二季度、第三季度和第四季度，表明分析師對這家臨牀階段生物技術公司的短期前景持更樂觀的看法。Dyne Therapeutics 分析師更新</li>
<li>積極情緒：HC Wainwright 維持對 DYN 的 “買入” 評級和 “$50 目標價”，儘管公司持續虧損，但仍強化了看漲觀點。HC Wainwright 報告</li>
<li>中性情緒：Dyne Therapeutics 表示管理層將參加即將舉行的投資者會議，這是一次常規的投資者關係更新，可能有助於保持股票的關注，但本身並不會改變基本面。Dyne Therapeutics 投資者會議</li>
<li>消極情緒：一些長期預期被下調，包括 2027 財年、2028 財年、2029 財年和 2030 財年每股收益預測，這可能會抑制對 Dyne 長期收益路徑的熱情。Dyne Therapeutics 長期預期下調</li>
</ul>
<h2>關於 Dyne Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Dyne Therapeutics 是一家臨牀階段的生物技術公司，專注於為嚴重罕見疾病開發局部基因調控療法。該公司的專有 FORCE（促進的正交受體介導的載荷評估）平台旨在實現寡核苷酸和基因治療方式的靶向遞送，主要針對骨骼和呼吸肌肉。Dyne 的主要項目集中在杜氏肌營養不良症（DMD）、肌強直性營養不良症 1 型（DM1）和麪肩肱肌營養不良症（FSHD），目前正在進行安全性、耐受性和組織特異性的臨牀前和早期臨牀研究。</p>
<p>自 2019 年由 Flagship Pioneering 創立以來，Dyne 利用其模塊化遞送方法推進了多個產品候選者，該方法將工程化配體與治療載荷結合，以改善肌肉細胞的攝取。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們認為比 Dyne Therapeutics 更好的股票</li>
<li>Oklo 股票可能準備再次大幅上漲</li>
<li>D-Wave 的財報看起來疲弱，但投資者可能忽視了這一點</li>
<li>隨着 AI 反饋循環加劇，Nebius 的上行空間擴大</li>
<li>內部交易：Okta 和 Abbott 看到買入，Micron 內部人士賣出</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Dyne Therapeutics 嗎？</h2>
<p>在考慮 Dyne Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Dyne Therapeutics 並不在名單上。</p>
<p>雖然 Dyne Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得投資。</p>
<p>在這裏查看這五隻股票</p>

標普生物技術 3 倍做多 - Direxion

醫藥突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 ETF - SPDR

動態生物技術與基因組 ETF - Invesco

納斯達克生物科技指數 ETF - iShares Nasdaq

<p>HC Wainwright 將 Dyne Therapeutics (NASDAQ:DYN) 2026 年第二季度每股收益預期從（$0.76）上調至（$0.68），維持 “買入” 評級，目標價為 $50.00。市場對該公司全年收益的共識預期為每股（$2.97）。Dyne 的股票開盤價為 $18.44，市值為 $30.5 億。機構投資者持有該股票的 96.68%，最近的內部交易中，董事 Jason P. Rhodes 出售了 83,219 股。總體而言，Dyne Therapeutics 的共識評級為 “適度買入”，平均目標價為 $35.21</p>

<p>Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Investment analysts at HC Wainwright upped their Q2 2026 EPS estimates for shares of Dyne Therapeutics in a note issued to investors on Tuesday, May 12th. HC Wainwright analyst A. Ghosh now expects that the company will post earnings of ($0.68) per share for the quarter, up from their previous estimate of ($0.76). HC Wainwright has a &#34;Buy&#34; rating and a $50.00 price objective on the stock. The consensus estimate for Dyne Therapeutics' current full-year earnings is ($2.97) per share. HC Wainwright also issued estimates for Dyne Therapeutics' Q3 2026 earnings at ($0.68) EPS, Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($2.78) EPS, FY2027 earnings at ($2.27) EPS, FY2028 earnings at ($0.85) EPS, FY2029 earnings at $0.52 EPS and FY2030 earnings at $2.26 EPS.</p>
<div class="lb-trans"><p>Dyne Therapeutics, Inc.（納斯達克代碼：DYN - 免費報告）- HC Wainwright 的投資分析師在 5 月 12 日星期二向投資者發佈的報告中上調了 Dyne Therapeutics 2026 年第二季度每股收益（EPS）預期。HC Wainwright 分析師 A. Ghosh 現在預計該公司本季度每股收益為（$0.68），高於之前的預期（$0.76）。HC Wainwright 對該股票給予 “買入” 評級，目標價為 $50.00。市場普遍預計 Dyne Therapeutics 當前全年的每股收益為（$2.97）。HC Wainwright 還發布了 Dyne Therapeutics 2026 年第三季度每股收益預期為（$0.68），第四季度每股收益預期為（$0.68），2026 財年每股收益預期為（$2.78），2027 財年每股收益預期為（$2.27），2028 財年每股收益預期為（$0.85），2029 財年每股收益預期為 $0.52，2030 財年每股收益預期為 $2.26。</p>
</div><p>Get <strong>Dyne Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Dyne Therapeutics</strong> 警報：</p>
</div><p>Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same quarter in the previous year, the firm earned ($1.05) EPS.</p>
<div class="lb-trans"><p>Dyne Therapeutics（納斯達克代碼：DYN - 獲取免費報告）上一次發佈季度財報是在 5 月 11 日星期一。該公司報告本季度每股收益為（$0.73），超出市場普遍預期的（$0.77）$0.04。在去年同期，該公司每股收益為（$1.05）。</p>
</div><p>A number of other research firms have also issued reports on DYN. Morgan Stanley lowered their target price on shares of Dyne Therapeutics from $50.00 to $47.00 and set an &#34;overweight&#34; rating on the stock in a research note on Monday, March 2nd. Chardan Capital reiterated a &#34;buy&#34; rating and issued a $38.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 9th. Wall Street Zen lowered shares of Dyne Therapeutics from a &#34;sell&#34; rating to a &#34;strong sell&#34; rating in a research note on Saturday, May 2nd. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Finally, Jefferies Financial Group reiterated a &#34;buy&#34; rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Dyne Therapeutics currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $35.21.</p>
<div class="lb-trans"><p>其他一些研究公司也對 DYN 發佈了報告。摩根士丹利在 3 月 2 日的研究報告中將 Dyne Therapeutics 的目標價從 $50.00 下調至 $47.00，並對該股票給予 “增持” 評級。Chardan Capital 在 3 月 9 日的研究報告中重申了 “買入” 評級，並對 Dyne Therapeutics 的股票設定了 $38.00 的目標價。華爾街 Zen 在 5 月 2 日的研究報告中將 Dyne Therapeutics 的股票評級從 “賣出” 下調至 “強烈賣出”。Weiss Ratings 在 4 月 20 日的研究報告中重申了對 Dyne Therapeutics 的 “賣出（d-）” 評級。最後，傑富瑞金融集團在 3 月 9 日的研究報告中重申了對 Dyne Therapeutics 的 “買入” 評級。三位投資分析師對該股票給予了強烈買入評級，十一位給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Dyne Therapeutics 目前的共識評級為 “適度買入”，平均目標價為 $35.21。</p>
</div><p><strong>Get Our Latest Research Report on Dyne Therapeutics</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Dyne Therapeutics 的最新研究報告</strong></p>
</div><h2>Dyne Therapeutics Stock Up 0.4%</h2>
<div class="lb-trans"><h2>Dyne Therapeutics 股票上漲 0.4%</h2>
</div><p>Dyne Therapeutics stock opened at $18.44 on Thursday. The company has a market capitalization of $3.05 billion, a P/E ratio of -5.73 and a beta of 1.08. The firm's fifty day simple moving average is $18.22 and its 200-day simple moving average is $18.63. The company has a current ratio of 19.92, a quick ratio of 22.25 and a debt-to-equity ratio of 0.17. Dyne Therapeutics has a 1-year low of $8.06 and a 1-year high of $25.00.</p>
<div class="lb-trans"><p>Dyne Therapeutics 股票在星期四開盤價為 $18.44。該公司的市值為 $30.5 億，市盈率為 -5.73，貝塔值為 1.08。該公司的 50 日簡單移動平均線為 $18.22，200 日簡單移動平均線為 $18.63。該公司的流動比率為 19.92，速動比率為 22.25，債務與股本比率為 0.17。Dyne Therapeutics 的一年低點為 $8.06，一年高點為 $25.00。</p>
</div><h2>Institutional Investors Weigh In On Dyne Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Dyne Therapeutics 的看法</h2>
</div><p>Several hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP lifted its stake in shares of Dyne Therapeutics by 870.3% in the first quarter. Dimensional Fund Advisors LP now owns 951,589 shares of the company's stock valued at $17,244,000 after buying an additional 853,515 shares during the period. Swiss National Bank lifted its stake in shares of Dyne Therapeutics by 2.5% in the first quarter. Swiss National Bank now owns 228,100 shares of the company's stock valued at $4,135,000 after buying an additional 5,600 shares during the period. Assetmark Inc. bought a new stake in shares of Dyne Therapeutics in the first quarter valued at about $563,000. Bank of New York Mellon Corp lifted its stake in shares of Dyne Therapeutics by 13.6% in the first quarter. Bank of New York Mellon Corp now owns 401,616 shares of the company's stock valued at $7,281,000 after buying an additional 48,119 shares during the period. Finally, Fifth Third Bancorp bought a new stake in shares of Dyne Therapeutics in the first quarter valued at about $983,000. Institutional investors own 96.68% of the company's stock.</p>
<div class="lb-trans"><p>幾家對沖基金最近對該股票的持倉進行了調整。Dimensional Fund Advisors LP 在第一季度將其在 Dyne Therapeutics 的股份增加了 870.3%。Dimensional Fund Advisors LP 現在擁有 951,589 股該公司的股票，價值 $17,244,000，此前在此期間又購買了 853,515 股。瑞士國家銀行在第一季度將其在 Dyne Therapeutics 的股份增加了 2.5%。瑞士國家銀行現在擁有 228,100 股該公司的股票，價值 $4,135,000，此前在此期間又購買了 5,600 股。Assetmark Inc. 在第一季度購買了 Dyne Therapeutics 的新股份，價值約 $563,000。紐約梅隆銀行在第一季度將其在 Dyne Therapeutics 的股份增加了 13.6%。紐約梅隆銀行現在擁有 401,616 股該公司的股票，價值 $7,281,000，此前在此期間又購買了 48,119 股。最後，Fifth Third Bancorp 在第一季度購買了 Dyne Therapeutics 的新股份，價值約 $983,000。機構投資者持有該公司 96.68% 的股份。</p>
</div><h2>Insider Buying and Selling at Dyne Therapeutics</h2>
<div class="lb-trans"><h2>Dyne Therapeutics 的內部買賣</h2>
</div><p>In related news, Director Jason P. Rhodes sold 83,219 shares of the stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $18.18, for a total value of $1,512,921.42. Following the completion of the sale, the director owned 7,962 shares in the company, valued at approximately $144,749.16. This trade represents a 91.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,552,911 shares of company stock valued at $29,694,469 in the last three months. 14.14% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相關消息中，董事 Jason P. Rhodes 於 5 月 6 日星期三出售了 83,219 股該股票。股份以平均價格 $18.18 出售，總價值為 $1,512,921.42。出售完成後，該董事在公司中持有 7,962 股，價值約 $144,749.16。此交易代表其持股比例減少了 91.27%。該交易已在證券交易委員會的備案中披露，可以通過此超鏈接訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。內部人士在過去三個月內共出售了 1,552,911 股公司股票，價值 $29,694,469。目前公司內部人士持有 14.14% 的股票。</p>
</div><h2>More Dyne Therapeutics News</h2>
<div class="lb-trans"><h2>更多 Dyne Therapeutics 新聞</h2>
</div><p>Here are the key news stories impacting Dyne Therapeutics this week:</p>
<div class="lb-trans"><p>以下是本週影響 Dyne Therapeutics 的主要新聞：</p>
</div><ul>
<li>Positive Sentiment: HC Wainwright and Lifesci Capital both raised near-term earnings estimates for Dyne Therapeutics, including Q2, Q3, and Q4 2026, suggesting analysts see a better short-term outlook for the clinical-stage biotech. Dyne Therapeutics analyst updates</li>
<li>Positive Sentiment: HC Wainwright kept its <strong>Buy</strong> rating and <strong>$50 price target</strong> on DYN, reinforcing a bullish view despite the company’s ongoing losses. HC Wainwright note</li>
<li>Neutral Sentiment: Dyne Therapeutics said management will participate in upcoming investor conferences, a routine investor-relations update that may help keep the stock in focus but does not by itself change fundamentals. Dyne Therapeutics investor conferences</li>
<li>Negative Sentiment: Some longer-dated estimates were cut, including FY2027, FY2028, FY2029, and FY2030 EPS forecasts, which may temper enthusiasm about Dyne’s long-term earnings path. Dyne Therapeutics longer-term estimate cuts</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：HC Wainwright 和 Lifesci Capital 都上調了 Dyne Therapeutics 的近期收益預期，包括 2026 年第二季度、第三季度和第四季度，表明分析師對這家臨牀階段生物技術公司的短期前景持更樂觀的看法。Dyne Therapeutics 分析師更新</li>
<li>積極情緒：HC Wainwright 維持對 DYN 的 “買入” 評級和 “$50 目標價”，儘管公司持續虧損，但仍強化了看漲觀點。HC Wainwright 報告</li>
<li>中性情緒：Dyne Therapeutics 表示管理層將參加即將舉行的投資者會議，這是一次常規的投資者關係更新，可能有助於保持股票的關注，但本身並不會改變基本面。Dyne Therapeutics 投資者會議</li>
<li>消極情緒：一些長期預期被下調，包括 2027 財年、2028 財年、2029 財年和 2030 財年每股收益預測，這可能會抑制對 Dyne 長期收益路徑的熱情。Dyne Therapeutics 長期預期下調</li>
</ul>
</div><h2>About Dyne Therapeutics</h2>
<div class="lb-trans"><h2>關於 Dyne Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.</p>
<div class="lb-trans"><p>Dyne Therapeutics 是一家臨牀階段的生物技術公司，專注於為嚴重罕見疾病開發局部基因調控療法。該公司的專有 FORCE（促進的正交受體介導的載荷評估）平台旨在實現寡核苷酸和基因治療方式的靶向遞送，主要針對骨骼和呼吸肌肉。Dyne 的主要項目集中在杜氏肌營養不良症（DMD）、肌強直性營養不良症 1 型（DM1）和麪肩肱肌營養不良症（FSHD），目前正在進行安全性、耐受性和組織特異性的臨牀前和早期臨牀研究。</p>
</div><p>Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.</p>
<div class="lb-trans"><p>自 2019 年由 Flagship Pioneering 創立以來，Dyne 利用其模塊化遞送方法推進了多個產品候選者，該方法將工程化配體與治療載荷結合，以改善肌肉細胞的攝取。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Dyne Therapeutics</li>
<li>Oklo Stock Could Be Ready for Another Massive Run</li>
<li>D-Wave Earnings Looked Weak, But Investors May Be Missing This</li>
<li>Nebius Upside Expands as AI Feedback Loop Intensifies</li>
<li>Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Dyne Therapeutics 更好的股票</li>
<li>Oklo 股票可能準備再次大幅上漲</li>
<li>D-Wave 的財報看起來疲弱，但投資者可能忽視了這一點</li>
<li>隨着 AI 反饋循環加劇，Nebius 的上行空間擴大</li>
<li>內部交易：Okta 和 Abbott 看到買入，Micron 內部人士賣出</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=DYN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Dyne Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Dyne Therapeutics 嗎？</h2>
</div><p>Before you consider Dyne Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Dyne Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Dyne Therapeutics 並不在名單上。</p>
</div><p>While Dyne Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Dyne Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得投資。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

HC Wainwright Has Optimistic Outlook of DYN Q2 Earnings

Market Beat

Dyne Therapeutics

摩根士丹利

Jefferies Financial

紐約梅隆銀行

五三銀行

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

BANK OF NEW YORK MELLON CORP DEP SHS REPG 1/4000TH INT SER K PFD

五三銀行-存託優先股Series K

Fifth Third Bancorp Pref Shares FITBM 6.875 Perp 10/01/30

五三銀行-Series A

HC Wainwright 對 Dyne Therapeutics 第二季度的收益持樂觀態度